Keen Scientific was contracted by a small pharmaceutical company to complete a protocol a phase II clinical trial in oncology. Timely completion of a quality protocol led to an almost year-long partnership where we completed 4 additional protocols and amendments, 3 clinical study reports, patient narratives and updates for 1 trial, and FDA communications for an Investigational New Drug (IND).
In addition to the clinical and regulatory writing services, we engaged the Medical Publications unit of the same company to complete 1 congress abstract and a lay summary of landmark trial.
Keen Scientific extended the partnership by providing reliable, high-quality services which span the entire lifecycle of the therapeutic product.